Skip to search formSkip to main contentSkip to account menu

DC 015

Known as: DC-015 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

DL-028

Broader (1)

Quinazolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1996
1996
Pharmacological activity of DC-015, a novel potent and selective alpha 1-adrenoceptor antagonist.
The pharmacological activity of 3-((4-(2-methoxyphenyl)piperazin-1-yl)methyl)-2,3-dihydroimidaz o(1,2 -c)quinazolin-5(6H)-one (DC… 
1996
1996
EFFECTS OF DC‐015, A NOVEL POTENT AND SELECTIVE α1‐ADRENOCEPTOR ANTAGONIST ON PLASMA LIPID AND VASCULAR REACTIVITY IN HYPERLIPIDAEMIC RATS
1. The effects of DC‐015, a newly synthesized quinazoline derivative, on plasma lipids, lipoprotein levels and vascular… 
1996
1996
Antihypertensive and Hypolipidemic Effects of DC-015, a Novel, Potent and Specific alpha(1)-Adrenoceptor Antagonist: Comparison with Prazosin in Spontaneously Hypertensive Rats.
The hypotensive effect of DC-015, a newly synthesized quinazoline derivative, was investigated and compared with prazosin in… 
1995
1995
Effect of DC-015, a novel potent and selective alpha 1-adrenoceptor antagonist, comparison with prazosin on noradrenaline-induced platelet aggregation.
The antiplatelet activity of DC-015, a newly synthesized quinazoline derivative was determined in human platelet-rich plasma… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)